Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) traded up 3% on Friday . The stock traded as high as C$0.51 and last traded at C$0.51. 81,399 shares changed hands during trading, an increase of 142% from the average session volume of 33,657 shares. The stock had previously closed at C$0.50.
Alpha Cognition Stock Performance
The company has a market cap of C$55.54 million, a price-to-earnings ratio of -3.92 and a beta of 2.86. The company has a fifty day moving average of C$0.57 and a two-hundred day moving average of C$0.47.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
See Also
- Five stocks we like better than Alpha Cognition
- Energy and Oil Stocks Explained
- 3 Stocks Leading the U.S. Agriculture Comeback
- Do ETFs Pay Dividends? What You Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Where to Find Earnings Call Transcripts
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
